Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

335
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
335
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

843
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
843
Autoimmune Disorders01:29

Autoimmune Disorders

1.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.2K
T Cell Types and Functions01:24

T Cell Types and Functions

1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional insights into autoantibodies targeting muscarinic acetylcholine receptors in Sjögren's disease.

Annals of the rheumatic diseases·2026
Same author

[Extracorporeal immunomodulation in sepsis : Role, limits, and perspectives of adjuvant blood purification therapies].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2026
Same author

Antibodies against Ro52 in idiopathic inflammatory myopathies are associated with objective sicca symptoms.

Frontiers in immunology·2026
Same author

Nuclear protein 1 is a cell death regulator in primary human airway epithelial cells and reduced in idiopathic pulmonary fibrosis.

Scientific reports·2026
Same author

The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis.

Science advances·2026
Same author

Extracorporeal membrane oxygenation without invasive mechanical ventilation for acute respiratory distress syndrome: an international cohort study.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Nov 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.6K

Immunomodulation in Autoimmune Interstitial Lung Disease.

Benjamin Seeliger1, Antje Prasse2,3

  • 1Department of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease (BREATH), German Center for Lung Research (DZL), Hannover, Germany, seeliger.benjamin@mh-hannover.de.

Respiration; International Review of Thoracic Diseases
|December 3, 2020
PubMed
Summary

Interstitial lung diseases (ILDs) linked to autoimmune conditions are common. This review covers synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) for managing ILDs, highlighting current evidence and treatment options.

Keywords:
ImmunomodulationImmunosuppressionInterstitial lung disease

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

640
Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

3.6K

Related Experiment Videos

Last Updated: Nov 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.6K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

640
Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

3.6K

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Autoimmune and systemic diseases frequently involve interstitial lung diseases (ILDs).
  • Understanding of ILD pathophysiology is rapidly advancing.
  • Current treatments for autoimmune-associated ILDs often rely on established disease-modifying antirheumatic drugs (DMARDs).

Purpose of the Study:

  • To summarize evidence on synthetic and biological DMARDs for ILDs associated with autoimmune/systemic diseases.
  • To review current treatment modalities for these complex lung conditions.
  • To highlight emerging therapeutic options based on recent clinical trials.

Main Methods:

  • Literature review of existing evidence on DMARDs in autoimmune-associated ILDs.
  • Analysis of retrospective data for established DMARDs.
  • Evaluation of recent randomized trials for biological DMARDs (bDMARDs).

Main Results:

  • Retrospective data primarily inform the use of conventional DMARDs in ILDs.
  • Randomized trials are increasingly evaluating bDMARDs for autoimmune-associated ILDs.
  • New treatment options are emerging for progressive ILD courses.

Conclusions:

  • Evidence for synthetic DMARDs in ILDs is largely retrospective.
  • bDMARDs represent a growing area of investigation and potential treatment for autoimmune-associated ILDs.
  • Comprehensive understanding of DMARD efficacy is crucial for managing these progressive lung diseases.